Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. (Q55463846)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Adrian F Ochsenbein

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Erik Vassella

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Luigi Mariani

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

21 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

343-351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20857319%20AND%20SRC:MED&resulttype=core&format=json

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Cognitive functions in low-grade gliomas: disease and treatment effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Prognostic factors for low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

A multigene predictor of outcome in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0395-2

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

21 January 2018

1 reference

12 December 2020

Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.

1 reference

12 December 2020

Brain tumors: molecular biology and targeted therapies

1 reference

12 December 2020

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

1 reference

12 December 2020

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas

1 reference

12 December 2020

MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue

1 reference

12 December 2020

Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis

1 reference

12 December 2020